InvestorsHub Logo
Followers 131
Posts 11471
Boards Moderated 0
Alias Born 01/06/2010

Re: None

Thursday, 10/19/2017 3:18:17 PM

Thursday, October 19, 2017 3:18:17 PM

Post# of 3881
Orphan designations are a dime a dozen these days...but it certainly doesn't hurt anything.


RedHill's upamostat an Orphan Drug in U.S. for pancreatic cancer
Oct. 19, 2017 11:44 AM ET|By: Douglas W. House, SA News Editor

The FDA designates RedHill Biopharma's (RDHL -0.8%) Phase 3-stage upamostat (MESUPRON) an Orphan Drug for the treatment of pancreatic cancer.

Among the benefits of Orphan Drug status in the U.S. is a seven-year period of market exclusivity for the indication, if approved.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent RDHL News